Table S1.
Treatment rate (physician perception data)
| UK (n = 50) | FR (n = 53) | DE (n = 63) | IT (n = 58) | ES (n = 54) | US (n = 160) | AR (n = 53) | JP (n = 69) | |
|---|---|---|---|---|---|---|---|---|
| No. of patients personally managed | 37.0 (13.8) | 37.5 (16.8) | 34.7 (11.1) | 25.9 (6.9) | 23.6 (6.4) | 57.9 (16.2) | 7.1 (2.3) | 7.5 (1.7) |
| No. of patients currently receiving PAH-specific therapy | 28.0 (13.0) | 33.6 (16.6) | 27.9 (8.9) | 21.7 (6.0) | 19.5 (5.4) | 49.3 (15.0) | 5.6 (1.5) | 6.4 (1.1) |
| Treatment rate, % | 76 | 89 | 80 | 84 | 83 | 85 | 79 | 85 |
Note
Responses to the study questions “How many individual PH patients are you currently managing?” and “How many of the PAH patients that are currently under your direct care, are currently treated with PAH-specific drug therapy?” Unless otherwise indicated, data are mean (SEM). AR: Argentina; DE: Germany; ES: Spain; FR: France; IT: Italy; JP: Japan; PAH: pulmonary arterial hypertension; PH: pulmonary hypertension; SEM: standard error of the mean; UK: United Kingdom; US: United States.